Effectiveness of the Combination of Water Aerobics and Metacognitive Training
- Conditions
- Psychosis
- Interventions
- Behavioral: Water aerobicsBehavioral: Metacognitive Training (MCT)Behavioral: Combined intervention
- Registration Number
- NCT05455593
- Lead Sponsor
- Fundació Sant Joan de Déu
- Brief Summary
The objective of this study is to assess the efficacy of a combined intervention of water aerobics and Metacognitive Training (MCT), compared to each intervention separately, in people with psychosis. One purpose is to analyze the improvement of clinical, cognitive, metacognitive and psychosocial variables, motor coordination and physical health condition. Another purpose is to study the changes in SP1 and SP4 biomarker transcription levels as a function of the intervention received. The hypothesis is that the combined intervention will enhance the benefits of each intervention separately, specifically in symptoms, cognition, metacognition and psychosocial variables.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Presence of one of the following diagnoses according to DSM-V criteria: schizophrenia, unspecific psychotic disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder.
- Psychopatological stability
- 18 to 55 years old
- Interested in participating in both water aerobics and MCT groups
- Head injury or intellectual disabillity (premorbid IQ <=70)
- Present scores on the PANSS >=5 in hostility, lack of cooperation or suspiciousness, to guarantee a good relationship in the group
- Patients with substance dependence disorder
- Problems related to water activities (phobia, severe mobility problems...)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Water aerobics Water aerobics Aerobic exercises performed in a swimming pool. Metacognitive Training (MCT) Metacognitive Training (MCT) Treatment program for psychosis based on Cognitive-behavioral therapy (CBT), cognitive remediation (CRT) and psychoeducation. Combined intervention (water aerobics + MCT) Combined intervention Combination of water aerobics and MCT sessions.
- Primary Outcome Measures
Name Time Method Change from Baseline Beads Task at 3 months (Brett-Jones et al., 1987) Baseline and 3-month follow-up Measure of jumping to conclusions bias. It includes two tasks in which two jars with colored beads are presented. The first task has a 85:15 proportion and the second task has a 60:40 proportion. In the third task, the jars contain positive and negative comments, with a proportion of 60:40 in each jar. The person has to infer from which jar the beads or comments are drawn. Jumping to conclusions bias is present when the participant decides after seeing up to two beads or comments.
Change from Baseline CBQ Cognitive Bias Questionnaire at 3 months (Peters et al, 2013; Gutiérrez-Zotes, 2021) Baseline and 3-month follow-up Measure of five cognitive biases (30 items): jumping to conclusions, intentionalising, catastrophising, emotional reasoning, and dichotomous thinking.
Change from Baseline BCIS Beck Cognitive Insight Scale at 3 months (Beck et al., 2004; Gutierrez-Zotes et al., 2012) Baseline and 3-month follow-up Cognitive insight self-registered measure (15 items): ability to analyze one's own beliefs and judgments. Self-reflectivness subscale: higher scores indicate a greater ability to reflect on one's own thoughts. Selfcertainty subscale: higher scores indicate a greater tendency to overestimate one's own beliefs without considering alternative explanations. Composite index: higher scores indicate a greater cognitive insight.
Change from Baseline Stress Test at 3 months Baseline and 3-month follow-up Assessment of clinical and sports records, cardiorespiratory and locomotor system examination, electrocardiogram and ergometry.
Change from Baseline Molecular measures at 3 months Baseline and 3-month follow-up Protein levels of SP1 and SP4 biomarkers transcription factor levels in peripheral blood mononuclear cells (PBMCs). mRNA expression levels of SP1 and SP4 biomarkers transcription factors in PBMCs.
- Secondary Outcome Measures
Name Time Method Change from Baseline Rosenberg self-esteem scale at 3 months (Martín Albó et al, 2007) Baseline and 3-month follow-up Self-esteem measure with 10 items (scores 0 to 30). Higher scores indicate greater self-esteem. Scores below 15 may indicate problematic low self-esteem.
Change from International Physical Activity Questionnaire (IPAQ; Booth, 2000) at 3 months Baseline and 3-month follow-up Intensity of physical activity and sitting time
Change from Oviedo Sleep Questionnaire (OSQ; Bobes et al., 2000) at 3 months Baseline and 3-month follow-up Sleep quality
Change from Baseline PANSS Positive and Negative Syndrome Scale at 3 months (Kay et al., 1987; Peralta y Cuesta, 1995) Baseline and 3-month follow-up Semi-structured interview to assess positive, negative and general symptoms of psychosis. Higher scores indicate greater severity of symptoms.
Change from Baseline BDI-II Beck Depression Inventory-II at 3 months (Beck et al., 1996) Baseline and 3-month follow-up Depressive symptoms
Change from Baseline IPSAQ Internal, Personal and Situational Attributions Questionnaire at 3 months (McArthur, 1972; Bentall et al, 1991; Diez-Alegría, 2006) Baseline and 3-month follow-up Attributional Style, including externalizing and personalizing bias subscales.
Change from Baseline Hinting Task at 3 months (Corcoran, Mercer & Frith, 1995) Baseline and 3-month follow-up Theory of mind
Change from Baseline Faces test at 3 months (Baron Cohen, 1997; Huerta-Ramos et al., 2021) Baseline and 3-month follow-up Facial emotion recognition
Change from Baseline MATRICS Consensus Cognitive Battery at 3 months (Nuechterlein et al., 2008; Rodriguez-Jimenez et al., 2012) Baseline and 3-month follow-up Verbal processing speed, verbal fluency, attention, working memory, verbal learning and memory, visual learning and memory, reasoning, problem solving.
WAIS-IV (Weschler Adults Intelligence Scale, 1955) Baseline Premorbid IQ assessed with the Vocabulary subscale
Change from Baseline GAF Global Assessment of Functioning at 3 months (Endicot et al., 1976) Baseline and 3-month follow-up General functioning in a scale of 0-100
Change from Baseline WHO-DAS 12, Psychiatric Disability Assessment Schedule at 3 months (WHO, 1988; Vázquez-Barquero JL, 2000) Baseline and 3-month follow-up Self-administered 12-item disability assessment
Change from Baseline SSQ Self Stigma Questionnaire at 3 months (Ochoa et al., 2015) Baseline and 3-month follow-up Self-administered 14-item scale to assess self-stigma
Change from Heart Rate at 3 months Baseline and 3-month follow-up Beats per minute (bpm)
Change from Baseline EuroQoL EQ-5D at 3 months (Badia et al., 1999) Baseline and 3-month follow-up Self-administered 5-item to assess general quality of life
Change from Baseline SUMD Scale to Assess Unawareness of Mental Disorder at 3 months (Amador X.F., et al.; 1993; Ruiz A., et al., 2008) Baseline and 3-month follow-up 3 items to assess awareness of having a mental illness, awareness of medication effects and awareness of social consequences of having a mental illness, in a scale of 0-15. Higher scores mean a worse outcome.
Change from Blood Pressure at 3 months Baseline and 3-month follow-up Millimetre of mercury (mmHg)
Change from Weight at 3 months Baseline and 3-month follow-up Kilogram (Kg)
Change from Height at 3 months Baseline and 3-month follow-up Centimetre (cm)
Change from Body Mass Index (BMI) at 3 months Baseline and 3-month follow-up Weight and height will be combined to report BMI in kg/m\^2
Change from Glucose Levels at 3 months Baseline and 3-month follow-up Milligrams per decilitre (mg/dL)
Change from Total Cholesterol at 3 months Baseline and 3-month follow-up Milligrams per decilitre (mg/dL)
Change from HDL Cholesterol at 3 months Baseline and 3-month follow-up Milligrams per decilitre (mg/dL)
Change from LDL Cholesterol at 3 months Baseline and 3-month follow-up Milligrams per decilitre (mg/dL)
Change from Body Abdominal Girth at 3 months Baseline and 3-month follow-up Centimetre (cm)
Trial Locations
- Locations (1)
Parc Sanitari Sant Joan de Déu
🇪🇸Sant Boi De Llobregat, Barcelona, Spain